Skip to main content
Neuro-Oncology logoLink to Neuro-Oncology
. 2020 Dec 4;22(Suppl 3):iii402. doi: 10.1093/neuonc/noaa222.538

MBRS-22. SIGNIFICANCE OF RNF213 IN TUMORGENICITY OF MEDULLOBLASTOMA

Yohei Mineharu 1, Yuki Oichi 1, Takahiko Kamata 1, Yasuzumi Matsui 1, Takaaki Morimoto 1,2, Masahiro Tanji 1, Hatasu Kobayashi 1,3, Hiroko Okuda 1, Kouji H Harada 1, Akio Koizumi 1,4, Yoshiki Arakawa 1, Susumu Miyamoto 1
PMCID: PMC7715166

Abstract

RNF213 gene, initially identified as a disease-causing gene for moyamoya cerebrovascular disease, has recently been recognized as a tumor regulator. The gene is known to be associated with WNT signaling, lipid metabolism, angiogenesis and genomic instability. The purpose of this study was to investigate the association of RNF213 in tumorgenicity of medulloblastoma. Incidence of medulloblastoma and histopathological findings were compared among ptch1+/-, ptch1+/- rnf213+/-, and ptch1+/- rnf213-/- mice. Knockout of rnf213 in ptch1+/- transgenic mouse model increased the incidence of spontaneous generation of medulloblastoma from 19.8% (ptch1+/-) to 76.5% (rnf213+/- ptch1+/-) at 9 months (p < 0.001). Heterozygous knockout was equivalent to homozygous knockout. Haploinsufficiency of rnf213 seems to be associated with tumorgenicity in medulloblastoma. Molecular mechanism of medulloblastoma generation needs to be further investigated.


Articles from Neuro-Oncology are provided here courtesy of Society for Neuro-Oncology and Oxford University Press

RESOURCES